Evidence map›Paper›PMID 40560737›Full record

ArticleAging2025

Implications of the KHDC4-TRAF2 axis in the context of prostate cancer prognosis.

Su-Wei Hu, Chia-Chang Wu, Shao-Wei Dong, Kai-Yi Tzou, Chih-Heng Chen, Yuan-Hung Wang, Yen-Nien Liu, Chiao-Chun Liao, Chien-Hsiu Li

Abstract read
In one paragraph

Article in Aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Su-Wei HuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Chia-Chang WuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Shao-Wei DongDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Kai-Yi TzouDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Chih-Heng ChenDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Yuan-Hung WangGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan.
Yen-Nien LiuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei City, Taiwan.
Chiao-Chun LiaoDepartment of Tropical Medicine, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Chien-Hsiu LiDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inability to effectively identify the formation of advanced-stage tumors poses a challenge in precisely determining when to intervene in prostate cancer (PCa). Despite the use of PSA as a screening factor, it still falls short in significantly improving the diagnosis and prognosis of advanced PCa. Identifying novel prognosis biomarkers to assist in confirming the progression of advanced PCa will contribute to more precise and effective therapeutic approaches. Through a comparative analysis between late-stage and early-stage TCGA-PRAD transcriptomes, KHDC4 has been identified as a key and specific member of the KHDC family that shows increased expression in PCa. The elevated levels of KHDC4 in late-stage and lymph node metastasis are positively correlated with poorer overall survival and disease-free survival rates in PCa patients. Simulated molecular regulation networks and

Indexed as

Prostatic NeoplasmsTNF Receptor-Associated Factor 2Biomarkers, TumorGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMalePrognosisBiomarkers, TumorTNF Receptor-Associated Factor 2bioinformaticKHDC4prognosisprostate cancerTRAF2

Identifiers

PMID40560737
PMCPMC12245195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.